A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients-Reference-Cited by-同舟云学术

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

Published:2011-09-26 Issue:5 Volume:155 Page:580-587
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Berenson James R.,Yellin Ori,Chen Chien-Shing,Patel Ravi,Bessudo Alberto,Boccia Ralph V.,Yang Hank H.,Vescio Robert,Yung Elizabeth,Mapes Russell,Eades Benjamin,Hilger James D.,Wirtschafter Eric,Hilger Jacqueline,Nassir Youram,Swift Regina A.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08884.x/fullpdf

Reference32 articles.

1. VAD-based regimens as primary treatment for multiple myeloma;Alexanian;American Journal of Hematology,1990

2. Effective treatment of advanced multiple myeloma refractory to alkylating agents;Barlogie;New England Journal of Medicine,1984

3. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma;Berenson;Journal of Clinical Oncology,2006

4. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen;Berenson;European Journal of Haematology,2009

5. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid;Berenson;American Journal of Hematology,2011

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients;Targeted Oncology;2023-09

2. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study;Annals of Hematology;2021-05-14

3. Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety;Frontiers in Oncology;2021-03-25

4. Mangiferin offers protection against deleterious effects of pharmaceuticals, heavy metals, and environmental chemicals;Phytotherapy Research;2020-09-22

5. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma;British Journal of Haematology;2017-11-21